Viridian Therapeutics Inc Revenue Growth Rates (VRDN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Viridian Therapeutics Inc   (NASDAQ: VRDN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

VRDN's Revenue Growth by Quarter and Year

Viridian Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRDN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.14
FY 0.14

VRDNs Annual Revenue
Viridian Therapeutics Inc 's Revenue in the fiscal year 2025 $ 70.85 millions
Viridian Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.30 millions
Viridian Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.31 millions
Viridian Therapeutics Inc 's Revenue in the fiscal year 2022 $ 1.77 millions
Viridian Therapeutics Inc 's Revenue in the fiscal year 2021 $ 2.96 millions




VRDN Revenue first quarter 2026 Y/Y Growth Comment
Viridian Therapeutics Inc reported Revenue surge of 101.43% year on year in the first quarter 2026, to $ 0.14 millions, this is lower than Viridian Therapeutics Inc 's recent average Revenue surge of 4848.31%.

According to the results reported in the first quarter 2026, Viridian Therapeutics Inc achieved the best Revenue growth in Medical Laboratories industry. While Viridian Therapeutics Inc ' s Revenue doubling of 101.43% ranks overall at the positon no. 266 in the first quarter 2026.


VRDN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 33.33 % 28.57 % -94.17 %
3rd Quarter September - 100714.29 % 0 % -73.08 %
2nd Quarter June - 0 % -30 % -54.55 %
1st Quarter March 101.43 % 0 % -36.36 % -47.62 %
FY   - 23510 % -14.29 % -

Financial Statements
Viridian Therapeutics Inc 's first quarter 2026 Revenue $ 0.14 millions VRDN's Income Statement
Viridian Therapeutics Inc 's first quarter 2025 Revenue $ 0.07 millions Quarterly VRDN's Income Statement


VRDN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -99.83 % 28.57 % 0 %
3rd Quarter September - 100714.29 % 0 % -30 %
2nd Quarter June - 0 % 0 % -9.09 %
1st Quarter March 17.5 % -22.22 % 0 % -90.83 %
FY (Year on Year)   - 23510 % -14.29 % -


Back to VRDN Growth rate Comparisons >> Back to VRDN Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #72
Overall #266

Revenue Y/Y Growth Statistics
High Average Low
81958.14 % 4848.31 % -93.97 %
(Sep 30 2025)   (Mar 31 2024)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #72
Overall #266
Revenue Y/Y Growth Statistics
High Average Low
81958.14 % 4848.31 % -93.97 %
(Sep 30 2025)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Viridian Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
366.8 % 4.38 % -99.83 %
(Sep 30 2022)  


VRDN's I. Quarter Q/Q Revenue Comment
Viridian Therapeutics Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 17.5%, to $ 0.14 millions, from $0.12 millions in the fourth quarter.
VRDN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Viridian Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 522.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #86
Overall #522
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #86
Overall #522
Revenue Q/Q Growth Statistics
High Average Low
366.8 % 4.38 % -99.83 %
(Sep 30 2022)  


VRDN's I. Quarter Q/Q Revenue Comment
Viridian Therapeutics Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 17.5%, to $ 0.14 millions, from $0.12 millions in the fourth quarter.
VRDN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Viridian Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 522.


Viridian Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)
Cumulative Revenue 12 Months Ending $ 70.90 $ 70.84 $ 70.80 $ 0.30 $ 0.30
Y / Y Revenue Growth (TTM) 23378.15 % 23355.3 % 24483.33 % 4.86 % -3.82 %
Year on Year Revenue Growth Overall Ranking # 2595 # 1658 # 1448 # 2289 # 3049
Seqeuential Revenue Change (TTM) 0.1 % 0.05 % 23343.71 % 0 % 0 %
Seq. Revenue Growth (TTM) Overall Ranking # 5 # 985 # 1 # 1952 # 2952


Cumulative Revenue growth Comment
Viridian Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 23378.15% year on year, to $ 71 millions if the fiscal year would have ended in Mar 31 2026.
Viridian Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5453.69% and higher than 23355.3% growth in Dec 31 2025. Company had also second best Revenue growth in Medical Laboratories industry.
But from twelve months ended Dec 31 2025 rise was beneth at 0.1 % from $70.84 millions achieved in the period from Dec 31 2025 to Dec 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5453.69%.
The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 0.1 % increase from $70.84 millions in the period from Dec 31 2025 to Dec 31 2024.

In the Healthcare sector 364 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1658 to 2595.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 365
Overall # 2595

Revenue TTM Y/Y Growth Statistics
High Average Low
24483.33 %
 5453.69 %
-82.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 3
S&P 500 # 5
Cumulative Revenue growth Comment
Viridian Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 23378.15% year on year, to $ 71 millions if the fiscal year would have ended in Mar 31 2026.
Viridian Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5453.69% and higher than 23355.3% growth in Dec 31 2025. Company had also second best Revenue growth in Medical Laboratories industry.
But from twelve months ended Dec 31 2025 rise was beneth at 0.1 % from $70.84 millions achieved in the period from Dec 31 2025 to Dec 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5453.69%.
The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 0.1 % increase from $70.84 millions in the period from Dec 31 2025 to Dec 31 2024.

In the Healthcare sector 364 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1658 to 2595.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 365
Overall # 2595

Revenue TTM Y/Y Growth Statistics
High Average Low
24483.33 %
5453.69 %
-82.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 3
S&P 500 # 5




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VRDN's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Nuo Therapeutics Inc 168.82%$ 168.820 millions
Immunitybio inc 167.64%$ 167.639 millions
Allogene Therapeutics Inc 166.67%$ 166.667 millions
Ironwood Pharmaceuticals inc 158.87%$ 158.868 millions
Urogen Pharma Ltd 155.07%$ 155.069 millions
Agios Pharmaceuticals Inc 137.75%$ 137.749 millions
Uniqure N v 127.31%$ 127.313 millions
Madrigal Pharmaceuticals Inc 126.84%$ 126.839 millions
Marker Therapeutics inc 115.32%$ 115.320 millions
Mobia Medical Inc 113.28%$ 113.284 millions
Precision Optics Corporation Inc 108.04%$ 108.043 millions
Inspiremd Inc 107.97%$ 107.972 millions
Tarsus Pharmaceuticals Inc 106.87%$ 106.873 millions
Phathom Pharmaceuticals Inc 104.43%$ 104.429 millions
Profound Medical Corp 103.62%$ 103.625 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________102.69%$ 102.686 millions
Vivos Therapeutics Inc 101.63%$ 101.634 millions
Protagonist Therapeutics inc 99.03%$ 99.033 millions
Alnylam Pharmaceuticals Inc 96.43%$ 96.432 millions
Abcellera Biologics Inc 96.34%$ 96.340 millions
Viridian Therapeutics Inc 95.83%$ 95.833 millions
Alamar Biosciences Inc 94.46%$ 94.462 millions
Bioage Labs Inc 91.04%$ 91.041 millions
Tenon Medical Inc 89.94%$ 89.945 millions
Vaxart Inc 87.90%$ 87.905 millions
Cannapharmarx Inc 87.12%$ 87.124 millions
Ionis Pharmaceuticals Inc 86.98%$ 86.982 millions
Picard Medical Inc 85.48%$ 85.484 millions
Therapeuticsmd Inc 84.22%$ 84.224 millions
Rhythm Pharmaceuticals Inc 83.81%$ 83.806 millions


About Viridian Therapeutics Inc Revenue Growth Rates (VRDN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Viridian Therapeutics Inc De (CIK 1590750).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001590750-26-000018
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Viridian Therapeutics Inc De’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.